Do analysts recommend FNCH or ESLA?

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 676.70%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, FNCH or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is FNCH or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Estrella Immunopharma N/A N/A -397.36%

Do analysts prefer GOSS or FNCH?

Gossamer Bio currently has a consensus price target of $5.00, indicating a potential upside of 2,894.01%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer FNCH or ACTU?

Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 753.66%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, FNCH or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is FNCH or ACTU more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Actuate Therapeutics N/A -430.93% -180.86%

Do analysts recommend MIRA or FNCH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, MIRA or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is MIRA or FNCH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Finch Therapeutics Group N/A -69.14% -26.92%

Finch Therapeutics Group (FNCH) Competitors

$7.30 0.00 (0.00%)

As of 06/12/2026

Compare

FNCH vs. NBRV, ESLA, GOSS, ACTU, and MIRA

Should you buy Finch Therapeutics Group stock or one of its competitors? MarketBeat compares Finch Therapeutics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Finch Therapeutics Group include Nabriva Therapeutics (NBRV), Estrella Immunopharma (ESLA), Gossamer Bio (GOSS), Actuate Therapeutics (ACTU), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does Finch Therapeutics Group compare to Nabriva Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Finch Therapeutics Group has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Finch Therapeutics Group's return on equity of -69.14% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Nabriva Therapeutics	Neutral

Nabriva Therapeutics has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Summary

Finch Therapeutics Group beats Nabriva Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Estrella Immunopharma?

Finch Therapeutics Group (NASDAQ:FNCH) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Estrella Immunopharma had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Estrella Immunopharma and 0 mentions for Finch Therapeutics Group. Estrella Immunopharma's average media sentiment score of 0.94 beat Finch Therapeutics Group's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Estrella Immunopharma	Positive

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 676.70%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Estrella Immunopharma's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Estrella Immunopharma	N/A	N/A	-397.36%

Summary

Estrella Immunopharma beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Finch Therapeutics Group has lower revenue, but higher earnings than Gossamer Bio. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.81	-$170.37M	-$0.79	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Finch Therapeutics Group has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Gossamer Bio had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Gossamer Bio and 0 mentions for Finch Therapeutics Group. Gossamer Bio's average media sentiment score of 0.93 beat Finch Therapeutics Group's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Positive
Finch Therapeutics Group	Neutral

Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Gossamer Bio currently has a consensus price target of $5.00, indicating a potential upside of 2,894.01%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Gossamer Bio beats Finch Therapeutics Group on 11 of the 15 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Actuate Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Actuate Therapeutics had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Actuate Therapeutics and 0 mentions for Finch Therapeutics Group. Actuate Therapeutics' average media sentiment score of 0.62 beat Finch Therapeutics Group's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Actuate Therapeutics	Positive

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 753.66%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Finch Therapeutics Group's return on equity of -69.14% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Summary

Actuate Therapeutics beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

MIRA Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Finch Therapeutics Group's return on equity of -69.14% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for Finch Therapeutics Group. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Finch Therapeutics Group's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Finch Therapeutics Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MIRA Pharmaceuticals beats Finch Therapeutics Group on 9 of the 12 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FNCH vs. The Competition

Export

Metric	Finch Therapeutics Group	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.72M	$349.69M	$6.74B	$12.07B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	-0.83	N/A	24.14	24.57
Price / Sales	N/A	171.60	511.88	141.49
Price / Cash	N/A	22.44	27.48	37.92
Price / Book	0.51	4.75	10.47	6.78
Net Income	-$74.75M	-$141.03M	$3.56B	$337.32M
7 Day Performance	N/A	0.65%	0.87%	1.96%
1 Month Performance	-7.59%	-4.71%	1.82%	3.81%
1 Year Performance	-46.91%	48.08%	25.66%	32.19%

Finch Therapeutics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
ESLA Estrella Immunopharma	3.0208 of 5 stars	$1.14 +9.6%	$8.00 +601.8%	+10.4%	$44.76M	N/A	N/A	N/A	Analyst Upgrade Gap Down High Trading Volume
GOSS Gossamer Bio	2.5241 of 5 stars	$0.18 -5.6%	$5.00 +2,712.1%	-86.9%	$44.19M	$48.47M	N/A	180	Gap Up
ACTU Actuate Therapeutics	2.0416 of 5 stars	$1.93 +6.0%	$17.50 +806.7%	-76.6%	$43.54M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. NBRV, ESLA, GOSS, ACTU, and MIRA

How does Finch Therapeutics Group compare to Nabriva Therapeutics?

Summary

How does Finch Therapeutics Group compare to Estrella Immunopharma?

Summary

How does Finch Therapeutics Group compare to Gossamer Bio?

Summary

How does Finch Therapeutics Group compare to Actuate Therapeutics?

Summary

How does Finch Therapeutics Group compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. NBRV, ESLA, GOSS, ACTU, and MIRA

How does Finch Therapeutics Group compare to Nabriva Therapeutics?

Do institutionals & insiders have more ownership in FNCH or NBRV?

Is FNCH or NBRV more profitable?

Which has more volatility & risk, FNCH or NBRV?

Does the media prefer FNCH or NBRV?

Which has preferable earnings & valuation, FNCH or NBRV?

Summary

How does Finch Therapeutics Group compare to Estrella Immunopharma?

Does the media prefer FNCH or ESLA?

Which has higher valuation and earnings, FNCH or ESLA?

Do analysts recommend FNCH or ESLA?

Do insiders and institutionals hold more shares of FNCH or ESLA?

Which has more volatility and risk, FNCH or ESLA?

Is FNCH or ESLA more profitable?

Summary

How does Finch Therapeutics Group compare to Gossamer Bio?

Which has stronger earnings and valuation, GOSS or FNCH?

Is GOSS or FNCH more profitable?

Do insiders & institutionals believe in GOSS or FNCH?

Does the media favor GOSS or FNCH?

Which has more risk and volatility, GOSS or FNCH?

Do analysts prefer GOSS or FNCH?

Summary

How does Finch Therapeutics Group compare to Actuate Therapeutics?

Does the media refer more to FNCH or ACTU?

Which has more volatility and risk, FNCH or ACTU?

Which has preferable earnings & valuation, FNCH or ACTU?

Do institutionals and insiders have more ownership in FNCH or ACTU?

Do analysts prefer FNCH or ACTU?

Is FNCH or ACTU more profitable?

Summary

How does Finch Therapeutics Group compare to MIRA Pharmaceuticals?

Which has better earnings & valuation, MIRA or FNCH?

Which has more risk and volatility, MIRA or FNCH?

Do insiders and institutionals have more ownership in MIRA or FNCH?

Is MIRA or FNCH more profitable?

Does the media prefer MIRA or FNCH?

Do analysts recommend MIRA or FNCH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools